Corrigendum to ''Correlating rrs and eis promoter mutations in clinical isolates of Mycobacterium tuberculosis with phenotypic susceptibility levels to the second-line injectables' ' [Int. J. Mycobacteriol. 5 (1) Unfortunately, we have realized that there are typographical errors in the final published version of the manuscript. We have highlighted the corrected sentences.
(a) In Materials and Methods under section of Quantitative DST:
Six concentrations of KAN and seven concentrations of AMK and CAP were used to establish the MICs for the M. tuberculosis isolates included in this study.
This should be corrected to Six concentrations of KAN and AMK; seven concentrations of CAP were used to establish the MICs for the M. Tuberculosis isolates included in this study.
(b) In Materials and Methods under section of setting and ethical approval:
Written consent was waived for all participants as the study was carried out on 90 archived isolates for which pyrosequencing, GenoTypeMTBDRslassay (version 1) and MGIT960 DST (utilizing WHO-approved critical concentrations) were previously performed. This should be changed to A written consent was waived for all participants as the study was carried out on 90 archived isolates, for which GenoTypeMTBDRslassay (version 1) and MGIT960 DST (utilizing WHO-approved critical concentrations) had been previously performed. Pyrosequencing was performed on 20 representative isolates.
(c) In Results: Titled '' I n t e r n a t i o n a l J o u r n a l o f M y c o b a c t e r i o l o g y 5 ( 2 0 1 6 ) 3 7 0 -3 7 2
Av ai la bl e at w w w . s c i e n c e di r e c t .c om Sixty phenotypically XDR-TB strains were included in this study. Eleven (found to have eis promoter mutations) were resistant to KAN at the critical concentration, but sensitive to AMK and CAP. Forty-eight isolates (determined to have the rrs A1401G mutation) were found to be resistant to KAN, AMK, and CAP. One isolate (with WT sequences for both the rrs and eis promoter) was also resistant to KAN, AMK, and CAP at the critical concentration. Thirty isolates were pan susceptible to all drugs tested. The MICs of AMK, KAN, and CAP for all isolates are shown in Table 1 .
This should be changed to Phenotypic results: Of the eleven found to have eis promoter mutations eight were resistant to KAN at the critical concentration, but sensitive to AMK and CAP whereas, three were sensitive to AMK, KAN and CAP at critical concentration. Forty-eight isolates (determined to have the rrs A1401G mutation) were found to be resistant to KAN, AMK, and CAP. One isolate (with WT sequences for both the rrs and eis promoter) was also resistant to KAN, AMK, and CAP at the critical concentration. Thirty isolates were pan susceptible to all drugs tested.
Genotypic results:
The agreement between the GenoType MTBDRsl assay results (based solely upon the presence of resistance-associated rrsmutations) and the phenotypic DST was 97% for AMK, 96% for KAN, and 86% for CAP Should be changed to The agreement between the GenoType MTBDRsl assay results (based solely upon the presence of resistance-associated rrs mutations) and the phenotypic DST was 98.8% for AMK and CAP; 90% for KAN.
(e) At all instances of 0.625 for KAN and CAP; 0.25 for AMK the 6 symbol needs to be included before the actual number, that is, 0.625 needs to be changed to 60.625 and 0.25 should be changed to 60.25.
Please also include this symbol 6 in Table 1 Isolates harboring the rrs A1401G mutation had AMK, KAN and CAP MICs of >40, >20, and 5-15 mg/L, respectively, whereas isolates with eis promoter mutations were found to have AMK, KAN and CAP MICs ranging from 0.25-1.0, 5.0-10, and 0.625-2.5 mg/L, respectively (Table 1) .
Should be changed to Isolates harboring the rrs A1401G mutation had AMK, KAN and CAP MICs of >40, >20, and 5-15 mg/L, respectively, whereas isolates with eis promoter mutations were found to have AMK, KAN and CAP MICs ranging from 60.25-1.0 mg/L, 60.625-10 mg/L, and 60.625-2.5 mg/L, respectively (Table 1) . The eis promoter mutations correlated with low-level AMK and CAP resistance, and moderate-level KAN resistance.
Should be changed to The eis promoter mutations correlated with low-level AMK and CAP resistance, and low to moderate-level KAN resistance.
(g) In Discussion;
The eis promoter mutations C-14T and G-10A corresponded to low-or moderate-level resistance to KAN, with KAN MICs generally ranging from 2.5 lg/mL to 10 lg/mL.
This should be changed to
The eis promoter mutations C-14T and G-10A corresponded to low-or moderate-level resistance to KAN, with KAN MICs ranging from 6 0.625 mg/L to 10 mg/L.
(h) Heading of the Table 2 i.e. Note: AMK = amikacin; CAP = capreomycin; DST = drug-susceptibility testing; KAN = kanamycin; PSQ = pyrosequencing; WT = wild type.
